Sabatolimab

Near Add Your Location

Accepting patients

MBG453

TIM3 Inhibition With MBG453 for Patients With Lower Risk MDS: an Adaptive Two-Stage Phase II Clinical Trial
Learn more
  • Monoclonal Antibody
  • TIM-3
  • Phase 2